Paradoxically, in BRCA1 and BRCA2 breast cancer tumors it seems that pCR does not serve as a surrogate marker of better clinical outcome and a higher pCR does not translate into improved disease-free and overall survival [71,72]. This evidence concerns the gene BRCA1 and breast cancer.